Current Colorectal Cancer Reports

, Volume 10, Issue 3, pp 251–253

To HIPEC or Not to HIPEC? That Is The Question



Colon cancer HIPEC Cytoreductive surgery 


  1. 1.
    Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15:938–46.Google Scholar
  2. 2.
    Goldberg RM, Fleming TR, Tangen CM, et al. Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med. 1998;129:27–35.PubMedCrossRefGoogle Scholar
  3. 3.
    Schellinx ME, von Meyenfeldt MF, Sugarbaker PH. Peritoneal carcinomatosis from adenocarcinoma of the colon. Cancer Treat Res. 1996;81:247–60.PubMedCrossRefGoogle Scholar
  4. 4.
    Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:3284–92.CrossRefGoogle Scholar
  5. 5.
    Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007–16.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Klaver YL, Hendriks T, Lomme RM, Rutten HJ, Bleichrodt RP, de Hingh IH. Hyperthermia and intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis: an experimental study. Ann Surg. 2011;254:125–30.PubMedCrossRefGoogle Scholar
  7. 7.
    Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:3191–8.CrossRefGoogle Scholar
  8. 8.
    Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.PubMedCrossRefGoogle Scholar
  9. 9.
    Andreasson H, Graf W, Nygren P, Glimelius B, Mahteme H. Outcome differences between debulking surgery and cytoreductive surgery in patients with Pseudomyxoma peritonei. Eur J Surg Oncol J Eur Soc Surg Oncol Br Ass Surg Oncol. 2012;38:962–8.Google Scholar
  10. 10.
    Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:3737–43.CrossRefGoogle Scholar
  11. 11.
    Dy GK, Hobday TJ, Nelson G, et al. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. Clin Colorectal Cancer. 2009;8:88–93.PubMedCentralCrossRefGoogle Scholar
  12. 12.
    Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:3677–83.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Hematology/OncologyMassachusetts General HospitalBostonUSA

Personalised recommendations